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Abstract
Objective: To investigate the use of rimabotulinumtoxinB (BoNT/B [Myobloc]) compared with placebo in treating hyperhidrosis in the residual
limbs of individuals with amputation.
Design: Randomized, double-blind, placebo-controlled pilot study.
Setting: Military medical center.
Participants: Male participants (NZ9) with 11 major amputations of the lower limbs and who complained of excessive sweating in their residual
limbs were enrolled in the study between September 24, 2008 to October 28, 2011. Participants’ lower limbs were randomly assigned to receive
injections of either BoNT/B (nZ7) or placebo (nZ4).
Intervention: BoNT/B.
Main Outcome Measures: The primary efficacy variable was a minimum of 50% reduction in sweat production 4 weeks after the injection as
measured via gravimetric sweat analysis after 10 minutes of physical exertion. Secondary analyses were performed on prosthetic function and
pain.
Results: All volunteers (100%; 7) in the BoNT/B group achieved a minimum of 50% reduction in sweat production as compared with only 50%
(2) in the placebo group. The percent reduction was significantly greater for the BoNT/B group than for the placebo group (72.7%15.7% vs
32.7%39.2%; P<.05). Although both groups subjectively self-reported significant sweat reduction and improved prosthetic function (P<.05
for both), objective gravimetric sweat analyses significantly decreased only for the BoNT/B group (2.32.3g vs 0.71.1g; P<.05). Neither group
reported a change in phantom limb pain or residual limb pain (P>.05 for both).
Conclusions: BoNT/B successfully reduces sweat production in individuals with residual limb hyperhidrosis, but does not affect pain. No
differences were found in perceived effect on prosthetic use between BoNT/B and placebo groups.
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Openwounded warriors now use upper and/or lower limb prostheses to
support independence, including activities of daily living and
mobility, as well as vocational and avocational participation.
Despite the advancement in prosthetic materials and components
over the past decade, 23% to 56% of individuals with limb loss
report excessive sweating (hyperhidrosis) of their residual limb(s)
that severely impedes their use of prostheses.2-4 The prevalence of
hyperhidrosis in individuals with limb loss is likely a result of
decreased body surface area, leading to inefficient heat access under CC BY-NC-ND license.
660 P.F. Pasquina et aldissipation, although it is unclear what determines whether an
individual will experience hyperhidrosis.5 The use of prosthetic
sockets and liners has been shown to contribute to hyperhidrosis
because the portion of the residual limb in contact with the
prosthesis is isolated from the outer environment, preventing
sweat evaporation or skin cooling.6 In addition, residual limb
sweating can contribute to excessive skin moisture, which when
coupled with shear and stress forces within a rigid prosthetic
socket, as well as the stasis of sweat within the socket, may lead to
secondary problems such as skin breakdown, dermatitis, and
infection. This may also result in decreased prosthetic use or even
prosthetic abandonment.7 Patients with limb amputation report
that the greatest dissatisfaction and frustration with their pros-
theses is due to excessive sweating.2,8 Therefore, the primary and
secondary effects of residual limb hyperhidrosis may have a sig-
nificant negative impact on function and quality of life in in-
dividuals with limb loss.
Current treatment options for residual limb sweating are less
than optimal. Antiperspirants or other topical agents, such as
aluminum chloride, must be reapplied frequently and may in-
crease skin irritation. Oral pharmacological management with
anticholinergic medications has limited efficacy because of un-
wanted side effects, such as dry mouth, tachycardia, and impaired
concentration and memory.9-11 Surgical procedures, including
endoscopic sympathectomy and sweat gland excision, are reserved
for extreme cases of hyperhidrosis and are often accompanied by
scars, infection, or restricted limb movement.12,13 Therefore, there
remains the need for a way to effectively treat hyperhidrosis at a
limited cost to the patient.
Comparatively, numerous case studies5,14,15 have corroborated
reduced focal hyperhidrosis and thus improved fit and function of
prostheses after treatment with onabotulinumtoxinA (BoNT/A).
An alternative serotype to BoNT/A is rimabotulinumtoxinB
(BoNT/B [Myobloc]). BoNT/B has been demonstrated to be
effective in reducing axillary and palmar hyperhidrosis.16,17 The
toxin functions to decrease sweating by blocking the release of
acetylcholine from postganglionic sympathetic fibers in the sweat
glands.18 Treatment of hyperhidrosis by BoNT/B is an off-label
use of the Food and Drug Administrationeapproved drug, but it
may be preferable to BoNT/A because of its wider radius of
diffusion, faster rate of onset, and higher affinity for autonomic
nerves.19-21 BoNT/B has shown similar efficacy to BoNT/A in
reducing palmar and residual limb hyperhidrosis in individuals
with amputation, as well as greater efficacy than that of BoNT/A
in decreasing phantom limb pain (PLP) and residual limb pain
(RLP).22-24 A case series by Kern et al22 of 9 lower limb amputees
receiving 1750U BoNT/B injections at the site of maximum
sweating reported a reduction in residual limb sweating, which
also contributed to significant improvements in the use of pros-
thetic devices, steadiness of gait, quality of life, and work per-
formance. They further reported a decrease in RLP in 8 of 9
participants.
However, previous studies of BoNT/B treatment of residual
limb hyperhidrosis, including the pilot study by Kern,22 haveList of abbreviations:
BoNT/A onabotulinumtoxinA
BoNT/B rimabotulinumtoxinB
PLP phantom limb pain
RLP residual limb pain
VAS visual analog scalerelied on subjective self-reporting of sweat reduction. To date, no
published studies have objectively measured sweat production in
the amputee population pre- and post-BoNT/B treatment. Given
the current lack of empirical data and absence of completed
placebo-controlled trials, we sought to assess via gravimetric
analysis whether BoNT/B treatment of individuals with lower
limb amputation causes a greater reduction in hyperhidrosis than
does placebo. Unlike surveys that rely on self-reported values,
gravimetric analysis quantifies the actual amount of sweat pro-
duced during a specific period of time spent executing a controlled
activity.25 Gravimetric analysis is less expensive than water
evaporation measurement methods, such as transepidermal water
loss, because it requires only the use of a filter paper and a scale,
and it can be more reliable than staining procedures for sweat
visualization.25
Thus, we aimed to reliably assess the effect of BoNT/B in-
jections on residual limb hyperhidrosis after amputation.
Secondarily, we report on PLP and RLP after BoNT/B treatment.Methods
Participants
After institutional review board approval from the Walter Reed
Army Medical Center, Washington, DC, which is now a part of
Walter Reed National Military Medical Center, Bethesda, MD, a
total of 9 participants with 11 lower limb amputations were
enrolled in the study. The threshold criterion for study entry was a
complaint of excessive sweating that negatively affected the fit
and/or function of the prosthesis. Excessive sweating was defined
as focal, visible sweating in the region of the residual limb. Par-
ticipants were excluded if they had inflammation, skin grafts, open
wounds, rashes, or other skin conditions in the residual limb; any
medical conditions that placed participants at increased risk with
exposure to BoNT/B; any systemic medical conditions that were
not medically managed or controlled at the time of recruitment;
and any condition or situation that, in the investigator’s opinion,
may have confounded the study results, including current or
planned use of aminoglycosides or preexisting medical conditions
that affect body temperature regulation. Participants provided
written informed consent before enrollment in the study.Procedures
The 11 lower limbs of the 9 participants were randomly assigned
to receive injections of either BoNT/B (nZ7) or placebo (nZ4)
by a computer-generated process carried out by the research
pharmacist. The pharmacist did not perform any study-related
assessments or data analyses, and study investigators were blinded
to randomization assignments. A log was kept by the research
pharmacist, linking each individual with a unique identifier to
either an active drug or a placebo group.
Participants received intradermal injections of either BoNT/B
diluted to 2500U/mL or placebo (0.9% isotonic saline) by using a
30-G hypodermic needle. Each injection was evenly spaced every
4 to 6cm2 in a grid pattern covering the surface area of the par-
ticipant’s residual limb that normally is in contact with their
prosthetic socket. A measurement of the inside depth of the
prosthetic socket was overlaid on the residual limb to determine
the surface area of skin normally in contact with the socket. Eachwww.archives-pmr.org















Male 7 (100) 4 (100) NA
Hours a day prosthesis
is worn
.412
0e8 4 (57.1) 1 (25) NA
8 3 (42.9) 3 (75) NA
Runs with prosthesis 3 (42.9) 2 (50) NA
Type of liner used .758
Silicone 2 (28.6) 2 (50) NA
Gel 3 (42.9) 2 (50) NA
None 2 (28.6) 0 (0) NA
NOTE. Values are mean  SD or n (%).
Abbreviation: NA, not applicable.
* At the time of the baseline visit.
Botulinum toxin for excessive sweating in amputees 661participant received a total of 4mL of either BoNT/B or placebo
per residual limb, except for 3 participants with 4 residual limbs
that had been amputated at the transfemoral level. For these in-
dividuals, a total of 8mL was needed to give an equivalent dose
per square centimeter of skin in contact with the prosthetic socket
regardless of the site of amputation. Therefore, a total of 10,000U
were used for individuals with transtibial amputation and 20,000U for
those with transfemoral amputation. Before the injection, a topical
anesthetic cream (30g of 4% topical lidocaine [EMLA]) or liberal
amounts of topical anesthetic mist spray (Gebauer’s Pain Ease) were
applied to the residual limb according to manufacturer’s instructions
to ameliorate injection pain. After the injection, participants were
instructed to continue to use whatever other sweat control treatments
(eg, antiperspirants and oral medications) they had been using before
the procedure, as needed. Participants were instructed to continue
their pretreatment sweat control methods and to not vary these
methods over the course of the study so that a variation would not
affect results. At each follow-up visit, all participants confirmed that
they had not varied their sweat control methods.
Gravimetric sweat analysis
Sweat production was objectively measured via gravimetric analysis.
This involved weighing a filter paper before and after its use for
absorbing perspiration. Before the injection, each participant was asked
to exercise on a treadmill, which entailed walking with their prosthesis
on at an exertion level of 11, or “light exertion” on the Borg Scale.26
After exercise, their residual limb and the liner were covered with the
filter paper (8.25-cm base) to absorb perspiration. After a total of 5
minutes, the filter paper from both the residual limb and the liner were
removed and weighed, and the value obtained was subtracted from the
weight of the dry filter paper to give the weight of the total sweat
produced. This same procedure was repeated 4 to 6 weeks after the
injection. The primary outcome measure used in this study was the
proportion of participants achieving a minimum of 50% reduction in
sweat production 4 to 6 weeks after the treatment.16 Room temperature
and percent humidity were measured and recorded at both the initial
session and the follow-up assessment during the administration of the
qualitative assessment, as well as the treadmill exercise test.
A qualitative assessment of sweating was also performed
during each study visit. Participants completed a sweating
assessment form (see supplemental appendix S1, available online
only at http://www.archives-pmr.org/) that consisted of questions
about the following: (1) perceived sweating; (2) perceived inter-
ference with prosthetic fit and function due to sweating; and (3)
severity of PLP and RLP, all rated on a 100-mm visual analog
scale (VAS).27 In addition, participants were asked about side
effects of the injection, pain perception of the procedure
(measured using a 100-mm VAS), and any changes in the use of
their prosthesis or prosthetic liner, as well as satisfaction with the
treatment and likelihood to seek it out in the future and/or
recommend it to a friend (measured using a Likert scale).27,28
Statistical analyses
Statistical analyses were performed for both the primary and the
secondary objectives using SPSS version 21.a A repeated-
measures analysis of variance was performed for each objective
to test the equality of means. In addition, an independent t test was
used to compare the percent changes in sweating between the
BoNT/B and placebo groups. Significance was determined to
be P<.05.www.archives-pmr.orgResults
Participants
A total of 9 male participants with either 1 or 2 major lower limb
amputations (total 11 limbs) who complained of excessive
sweating in their residual limb(s) were enrolled in the study be-
tween September 2010 and November 2012. The study population
was randomly assigned to 2 groups: BoNT/B (nZ7) or placebo
(nZ4) (tables 1 and 2). All participants were men with a mean age
of 25.04.0 years and with lower limb amputation(s) at either the
transfemoral (nZ4) or the transtibial (nZ7) level. In general,
participants tended to be within 2 years of their amputation, and
most of them reported wearing their prosthesis >8h/d.Sweating
Gravimetric analysis
All participants (100%; 11) who received BoNT/B met the primary
endpoint with respect to efficacy in sweat reduction, achieving a
minimum of 50% reduction in sweat production 4 to 6 weeks after the
treatment. The mean reduction for the BoNT/B group was 72.7%
15.7%. Comparatively, 50% of participants (2) who received placebo
met this primary endpoint with a mean reduction of only 32.7%
39.2%. Furthermore, the efficacy in sweat reduction was statistically
different between the 2 groups, with the BoNT/B group reporting a
significantly greater reduction than did the placebo group (P<.05).
Gravimetric sweat analyses were significantly decreased for
participants who received BoNT/B (P<.05) from a baseline
assessment mean of 2.32.3g to a follow-up assessment mean of
0.71.1g. Participants who received placebo did not have a sig-
nificant change in the amount of sweat produced (0.71.0 to
0.40.4g; P>.05) (fig 1).
Room temperature and percent humidity data revealed that for
the BoNT/B group, the average temperature during the assessment
Table 2 Participants’ demographic characteristics
Injection Age (y) Sex Level of Amputation Time Since Amputation (mo) Total Dose (mL)
BoNT/B 24 Male Transfemoral 8 8
BoNT/B 27 Male Transtibial 4 4
BoNT/B 23 Male Transtibial 13 4
BoNT/B 21 Male Transfemoral 18 8
BoNT/B 24 Male Transtibial 11 4
BoNT/B 33 Male Transtibial 12 4
BoNT/B 33 Male Transtibial 12 4
Placebo 26 Male Transtibial 27 4
Placebo 27 Male Transtibial 10 4
Placebo 21 Male Transfemoral 18 8
Placebo 23 Male Transfemoral 28 8
662 P.F. Pasquina et alwas 23.78C with an average humidity of 33.21%; during the
treadmill exercise test, temperature and humidity were 24.03C
and 33.61%, respectively. For the placebo group, the average
temperature during the assessment was 23.32C with a humidity
of 43.5%; during the treadmill exercise test, temperature and hu-
midity were 23.16C and 43.3%, respectively. There is a difference
of .46C in the average temperatures of the testing environments of
BoNT/B and placebo groups. Although there is a difference of
9.69% in the average humidity values of the testing environments of
the 2 groups, at this low temperature the measured temperature is
similar to the perceived temperature.29 According to a Universal
Scale of Apparent Temperature, at temperatures below 26.6C the
percent humidity does not affect the temperature perceived by the
human body and so even with the differences in humidity the
temperature in both rooms was experienced at the stated Celsius
reading. Therefore, the difference in humidity has little effect on
how much the participants perspired.
Qualitative self-report
Both BoNT/B and placebo groups reported a significant decrease
in sweat measurements from baseline to follow-up assess-
ments (P<.05 for both). For participants who received BoNT/B,
perceived sweating measurements decreased from 74.324.5
to 37.126.1mm, whereas for participants who received placebo,
perceived sweating measurements decreased from 75.014.1 to
39.530.0mm, as measured using a 100-mm VAS (fig 2). All





























Fig 1 Gravimetric sweat analysis showed a greater percent reduc-
tion in the BoNT/B group (67.3%15.7%; nZ7) than in the pla-
cebo group (27.3%39.2%; nZ4).pain from the injection would not prevent them from receiving
the study treatment in the future nor would it prevent them from
recommending it to others. When asked about their satisfaction
with the results of the treatment, all participants in both groups
responded neutral to strongly satisfied, whereas none reported
being dissatisfied or strongly dissatisfied with the treatment.
Secondary objectives
Interference with prosthetic function
Both BoNT/B and placebo groups reported a significant reduction
in sweat interference with prosthetic function from their baseline
assessment to their 4- to 6-week follow-up assessment, as
measured by self-report using a 100-mm VAS (P<.05 for both).
Pain
Neither PLP nor RLP changed for either the BoNT/B group or the
placebo group from baseline assessments to follow-up assess-
ments (P>.05 for all).Discussion
This study demonstrates that BoNT/B significantly reduces hy-
perhidrosis in the residual limbs of individuals with major lower


























Fig 2 Perceived sweating assessment showed similar sweat
measurements in both BoNT/B and placebo groups as measured by
self-report using a 100-mm VAS.
www.archives-pmr.org
Botulinum toxin for excessive sweating in amputees 663than placebo at reducing sweating 4 to 6 weeks after the injection.
All participants receiving BoNT/B injections exhibited a statisti-
cally meaningful decrease in the amount of sweat produced.
These results add to the body of literature expanding the
clinical therapeutic applications for BoNT/B. Although BoNT/B
is most commonly used to treat muscle disorders characterized
by inappropriate muscle contractions, spasms, and increased
tone,30 its efficacy in treating other conditions, such as hyper-
hidrosis, warrants further attention, especially from rehabilitation
professionals. BoNT/A (or Botox) has been used to successfully
manage focal hyperhidrosis of the palms, feet, or axillae.31-33 In
a number of clinical studies,5,15,34 BoNT/A has also proven
effective in treating excessive sweating of the residual limbs of
individuals with amputation. Only 1 pilot study thus far has
explored the effect of the alternative serotype, BoNT/B, on the
residual limb sweating in individuals with amputation. Kern22
reported a significant reduction in sweating of the residual limb
in a small case series of 9 individuals with amputation after
1750U BoNT/B injections; however, this study did not include
a placebo group and relied on subjective self-report to mea-
sure efficacy.
To our knowledge, this study is the first double-blind, placebo-
controlled, objectively measured pilot trial on the efficacy of
BoNT/B in the treatment of residual limb hyperhidrosis. Gravi-
metric analysis of sweat production yielded data that were both
unbiased and reproducible. Of interest, both groups (BoNT/B and
placebo) reported a decrease in perceived sweating measurements
from baseline to follow-up assessment. For the placebo group, this
report of decreased sweating is in contrast to quantitative findings
of no significant reduction. In addition, both groups after receiving
the injections reported a significant decrease in sweat interference
with prosthetic function, while neither group reported a statisti-
cally significant change in PLP or RLP over the course of treat-
ment. These findings support the findings of Charrow et al,5 who
found that BoNT/A had no effect on the severity of RLP or PLP,
but contrasted with the findings of Kern,22 who showed that
BoNT/B treatment leads to a decrease in RLP and PLP in in-
dividuals with limb amputation.
The unexpected finding that participants perceive a positive
treatment effect, despite objective gravimetric analyses, suggests
the presence of a strong placebo effect. Numerous studies35,36
have demonstrated that participants who received placebo have
clinical improvements identical or comparable to the changes
caused by actual medication. Similarly, the placebo effect may
have been a factor in the control participants’ self-analysis of
sweat interference with prosthetic function. This finding further
indicates that subjective reports of improvement in prosthetic
function require controlled trials to verify such findings.
Study limitations
There are several limitations to this pilot study. The small size of
both groups indicates that the findings should be interpreted
carefully in light of participants’ demographic characteristics and
study location. Our study population (mean age, 25.04.0y) was
younger than the general population, and all participants were
enlisted members of the military. It would be valuable to see this
study replicated in an older, civilian population. Furthermore,
limited long-term follow-up and fixed BoNT/B dosage preclude
definitive conclusions about the dosage and injection frequency
necessary to produce and maintain a positive response. Previous
studies22,37,38 have suggested that positive effects of BoNT/B lastwww.archives-pmr.orgbetween 3 and 6 months. Most people will require repeated in-
jections to have lasting effects, although it has also been reported
that some people may develop immune resistance to the toxin and
stop responding to treatment.39,40 Future studies would benefit
from confirmation of these findings on a larger scale. A larger
sample size would also ensure greater similarity in baseline sweat
profiles between groups, which is difficult to achieve with small
participant samples. In addition, a comparison of BoNT/B with
BoNT/A would be useful to determine which, if any, is more
efficacious. Finally, by including an observation control group
who receives no injection or has a run-in period, the role of time
and prosthetic use in sweat production could be assessed
more directly.Conclusions
This prospective, double-blind, placebo-controlled pilot study
demonstrates that BoNT/B effectively reduces hyperhidrosis in the
residual limbs of individuals with lower level amputation at 4 to 6
weeks after the injection. In addition, BoNT/B is objectively more
effective than placebo at reducing sweating in the residual limb,
but does not affect PLP or RLP. No differences were found in
perceived prosthetic function between BoNT/B and placebo
groups. Further research is warranted to investigate the optimal
dosage and frequency of BoNT/B injections into the residual limb
and to assess the longevity of their effect.Supplier
a. IBM Corp.
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Supplemental Appendix S1 Sweating Assessment Form
Date: ___________________________ Age: ____________________________
1. Over the previous month, how much sweating have you experienced in your residual limb?
[Please place a single dash “/” on the line that represents your answer]
_______________________________________________________
None Very Much
2. Over the previous month, how much has the sweating interfered with your prosthesis functioning?
[Please place a single dash “/” on the line that represents your answer]
_______________________________________________________
None Very Much
3. Over the previous month, how much has the sweating interfered with your prosthesis fitting?
[Please place a single dash “/” on the line that represents your answer]
_______________________________________________________
None Very Much
4. Please mark what your average amount of phantom pain is over the previous month.
[Please place a single dash “/” on the line that represents your answer]
__________________________________________________________
None Worst Pain Ever
5. Please mark what your average amount of residual limb pain is over the previous month.
[Please place a single dash “/” on the line that represents your answer]
__________________________________________________________
None Worst Pain Ever
6. Date of amputation: ______________________________
7. Date you began using a prosthesis on the limb with excessive sweating: ________________
8. Approximately how many hours per day do you wear your prosthesis?
9. Approximately how many minutes per week do you run in your prosthesis?
10. Type of liner you are currently using most frequently: ________________
11. Approximate amount of time you have been using this type of liner: ________________
12. Type of suspension system (eg, pinlock, lanyard, suction, vacuum) you are currently using most frequently: ________________
13. What other treatments for sweating have you tried (eg, antiperspirants, topical treatments such as aluminum chloride, oral medi-
cations, change in liner or suspension system)?
14. Of those treatments listed in item 13, which have you used in the previous week?
15. Please list all medications that you are currently taking: ________________
16. Have you ever been treated with botulinum toxin, Dysport, Botox, or Myobloc?
Yes No
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[THIS PAGE IS TO BE FILLED OUT AT THE END OF THE VISIT]
1. Make a tick mark along the scale below that represents the amount of pain you experienced related the injection of the medication.
____________________________________________________________________
No pain Worst possible pain
2. Please describe the TYPE of pain that you experienced related to the injection of the medication. For example, “Sharp Pain,” “Dull
Pain,” “Burning Pain,” “Stabbing Pain,”, OR USE YOUR OWN WORDS. You may use as many words to describe the pain as you like.
3. I would recommend this treatment to a fellow patient. (Circle one)
Strongly agree Agree Neutral Disagree Strongly disagree
4. The pain of the injections would prevent me from getting this treatment in the future. (Circle one)
Strongly agree Agree Neutral Disagree Strongly disagree
For follow-up visits ONLY:
5. I am satisfied with the results I experienced from receiving this treatment. (Circle one)
Strongly agree Agree Neutral Disagree Strongly disagree
6. I think this treatment helped reduce my sweating.
Strongly agree Agree Neutral Disagree Strongly disagree
[THIS PAGE IS TO BE FILLED OUT BY THE INVESTIGATOR]
Date: _______________________
Room temperature and humidity during questionnaire: ________________________
Target speed obtained in the treadmill walking phase: __________________________
Room temperature during the treadmill test: ________________________
Total weight of sweat produced in 5 minutes as measured by gravimetric analysis: ________
Pictures of residual limb with Minor’s (starch-iodine) test:
[Attach pictures here]
Number of vial used for injections: ___________________________
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